Home
About
Overview
Sharing Data
ORCID
Help
History (1)
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 2016 08; 57(8):1800-6.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Anemia
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Anti-Ulcer Agents
beta Catenin
Bone Marrow Cells
Carboplatin
Chemotherapy-Induced Febrile Neutropenia
Cohort Studies
Female
Glycogen Synthase Kinase 3
Heterocyclic Compounds, 3-Ring
Humans
Leukemia, Myeloid, Acute
Leukocytes, Mononuclear
Male
Maleimides
Middle Aged
Pain, Procedural
Pemetrexed
Protein Kinase Inhibitors
Ranitidine
Thrombocytopenia
authors with profiles
Olatoyosi Odenike